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Topical methylglyoxal bis(guanylhydrazone) (MGBG) 
previously has been shown to produce partial clinical 
improvement in psoriasis. To enhance therapeutic activ-
ity, studies were undertaken to optimize MGBG percu-
taneous penetration in vitro and to study biochemical 
changes related to epidermal proliferation in vivo. 
MGBG penetration in saline, Vehicle N, decylmethyl-
sulfoxide, and N-methylpyrrolidone was determined in 
normal human skin in vitro. Maximum penetration was 
obtained with 10% MGBG in Vehicle N (3 11-g/h/cm2 ) . 
Both topical and systemic MGBG resulted in increased 
levels of S-adenosyl-L-methionine decarboxylase, sug-
gesting an extended half-life as a consequence of MGBG 
binding. Topical treatment with 10% MGBG in Vehicle 
N also resulted in decreased epidermal polyamine levels. 
The changes in polyamine metabolism were also associ-
ated with inhibition of epidermal DNA synthesis. These 
studies suggest that this topical MGBG formulation may 
be a candidate for use in the treatment of psoriasis and 
other hyperproliferative cutaneous diseases associated 
with increased polyamine synthesis. 
The increased epidermal cell proliferation in psoriasis is 
assoc iated with elevated tissue levels of the polyamines putres-
cine, spermine, and spermidine, as well as increased activities 
of the polyamine biosynthet ic enzymes, ornithine decar-
boxylase (ODC) and S-adenosyl-L-methionine decarboxylase 
(SAMDC) [1 ,2] (Fig 1) . Various therapies effective in psoriasis, 
such as steroids, anthralin, PUV A, and etretinate all normalize 
polyamine abnormalities in parallel with clinical improvement 
[1,3,4]. These studies suggest that polyamines may play a role 
in the cellular regulatory factors in psoriasis and that modula-
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tion of polyamine metabolism by pharmacologic agents may 
therefore be useful for the treatment of this skin disorder. 
In a recent clinical screen of topical chemotherapeutic agents, 
methylglyoxal bis(guanylhydrazone) (MGBG) a strong com-
petitive inhibitor of SAMDC produced a partial therapeutic 
response in psoriasis ([5]. The topical formulation (10 % MGBG 
in saline) used in this clin ical trial was selected on an empirical 
basis without consideration for optimizing percutaneous pene-
tration. The present study was therefore undertaken to evaluate 
the percutaneous penetration of MGBG in vitro to enhance 
penetration and to determine the effects of the selected MGBG 
formu lations on epidermal DNA synthesis and polyamine me-
tabolism in hairless mice in vivo. 
MATERIALS AND METHODS 
Methylglyoxal bis(guanylhydrazone) dihydrochloride monohydrate 
(MGBG) was obtained from Aldrich Chemical Co., Milwaukee, Wis-
cc;msin; Vehicle N (alcohol 47.5%, water, laureth-4, isopropyl alcohol 
4%, propylene glycol) from Neutrogena Corp., Los Angeles, California; 
n-decylmelhyl sulfoxide (C 10MSO) from Cyclo Chemical Co., Los An-
geles, California; N-methylpyrrolidone from Nelson Research, Irvine, 
Cali fornia. [Methyl-3H]thymidine (spec act 25.0 Ci/ mmol) and S-
[ca rboxyl-' ''C]adenosyl-L-methioni ne (spec act 62.0 mCi/mmol) were 
purchased from Amersham, Arlington Heights, Illinois. TPA (1 2-0-
tetradecanoyl-phorbol-13-acetate) was purchased from Consolidated 
Midland Corporation, Brewster, New York. 
In Vitro Perwtaneous Penetration Studies 
The percutaneous penetration of MGBG was measured in glass 
diffusion cells by the technique previously described [6]. MGBG (0.5 
ml) in various vehic les was applied to the epidermal surface of excised 
norma l human autopsy sk in (0.2 ml/ cm2). The dermal reservoir con-
ta ined phosphate-buffered saline. Diffusion cells were incubated with 
constant stirring at 28"C. Three diffusion cells were run for each test 
condition. MGBG penetration was quantitated by high-performa nce 
liquid chromatographic (HPLC) analysis using the method previously 
described [7]. Samples of saline, Vehicle N, and C10MSO without 
MGBG were chromatographed a nd found to contain no peaks t hat 
interfered with MGBG a nalysis. Standard curves for MGBG in saline 
were constructed and used for quant itation . The reproducibility and 
c·urve fi t were excellent (r2 = 0.99). Percutaneous samples were chro-
matographed without further purification. 
The test solu tion was removed after the 48-h incubation period and 
the epidermal surface rinsed 3 times with the vehicle in which t he drug 
was dissolved. Th is process effectively removed a ll surface drug that 
had not penetrated the stratum corneum. The epidermis was separated 
by heating the skin for 1 min in a 60"C water bath . To extract MGBG 
from the epidermis, t issues were homogenized in 1 ml of saline afte r 
which 100 ,., I of 10 N perchloric acid was added. This was mixed well 
and centrifuged at 10,000 g for 10 min. One hundred microliters of 10 
N KOH was added to neut ralize the supernatant which was then 
assayed for MGBG content by HPLC as described above. 
In Vivo Studies 
HRS J albino hairless mice aged 2- 3 months were used for t hese 
experiments. 
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F IG 2. Effect of vehic le on 10% MGBG percutaneous penetration 
in vit ro. Vehicles: e, saline; .A. , N-methylpyrrolidone:isopropyl alco-
h ol:water (43:30: 27); •. decylmethylsulfoxide:water (2.5:97.5); 0 , Ve -
hicle N. A rrows indicate 48- h penetration of 0.1 % and 1.0% MGBG in 
Veh icle N. Mean values± SD for 3 diffusion cha mbers. 
l. Effects of MGBG on DNA synthesis. Fifty microli ters of MGBG 
in Vehicle N or Vehicle N a lone (control) was app lied to the backs of 
normal hai rless mice (6 mice/group) daily for eit her 3 or 7 days. S ix 
h ours a fte r the last application mice were injected with t ri t iated thy-
midine (2 11Ci/g body weight) . Another group of anima ls was simila rly 
t reated except that TPA (17 nmol in a tota l volume of 0.2 ml acetone) 
was app lied topica lly 12 h prior to t he administration of t ritiated 
t hymidine. One hou r a fter administrat ion of isotope, a nima ls were 
sacrificed by cervical dislocation and t reated skin excised. Epidermis 
was removed afte r incubating the skin specimens for 1 h at 37•c in 2 
M sodium bromide. DNA was extracted and assayed using t he technique 
described by Halprin et a l [8) . Resul ts of epiderma l DNA synt hesis 
were calculated as cpm per 11g DNA. Another group of 6 mice received 
systemic (i.p.) MGBG (50 mg/kg) at 12 and 6 h prior to t he adminis-
t ration of tritia ted t hymidine. Sk in biopsies were also processed for 
standa rd histology. 
2. Effects on polyamine biosynthesis. Fifty microli ters MGBG / Ve-
hicle N or Vehicle N (control) was applied dai ly for either 3 or 7 days 
o r given i.p. (50 mg/kg) at 6 a nd 12 h prior to sac rifice (8 mice/group). 
TPA (17 nmol) was app lied 12 h before sacrifice to stimulate epidermal 
S AMDC activity [9]. The dorsal skin samples were pooled from 4 
anima ls to determine SAM DC activity. SAMDC levels were determi ned 
in epidermal homogenates by the release of •·•co2 from S- [carboxyl-
'"C]adenosyl-methionine (SAM) as previously descr ibed [10]. 
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For dete rmining MG BG effects on polyamine levels, mice were 
t reated as desc ribed above (8 mice/treatment group) and dorsal skin 
samples from 2 mice were pooled for polyam ine a nalysis. Epiderma l 
polyamine levels were quantitated by an amino ac id analyzer using the 
technique previously descr ibed [11) . 
RESULTS 
In Vitro Percutaneous Penetration Studies 
The percutaneous penetration of 10% MGBG was deter-
mined in saline and 3 other vehicles that have been reported 
to enhance penetration of various drugs. There was an increase 
in penetration at 24 and 48 h in C10MSO and Vehicle N 
compared to saline (Fig 2). Vehicle N produced t he maximum 
rate of MGBG penetration of 3 ttg/h/ cm2 surface area of skin . 
There was a dose-dependent increase in MGBG penetration in 
TABLE I. In vitro percutaneous penetration study-epidermal MGBG 
content 
Vehicle 
Vehicle N 
CIOMSO: H20 (2.5 :97.5) 
Saline 
N- Methylpyrrol idone:isop ropyl 
alcohol:H20 (43:30:27) 
MGBG content of 
epidermis at 48 h 
(l'g (mean± SO)) 
525 ± 81 
1191 ± 266 
58 ± 25 
185 ± 85 
T en percent MGBG in the above vehicles was applied to the epider-
mal surface of human skin in vit ro. Upon completion of the study at 
48 h (Fig 2), epidermis was removed and MGBG content assayed as 
descr ibed in Materials and Methods. 
FIG 3. Effects of topical MGBG in Veh icle Non normal mouse sk in 
applied daily x7. A, Veh icle N cont rol. B, Ten percent MGBG. x 400. 
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FIG 4. Effects of topical MGBG in Vehicle Non TPA -treated mouse skin , applied daily x3; A, Vehicle N control. B, T en perce nt MGBG ; or 
applied dai ly X7 . C, Vehicle N co ntrol. D, Ten percent MGBF. x 400. 
Vehicle N comparing 0.1 %, 1%, and 10 % MGBG penetration 
at 48 h (F ig 2). The penetration of 0.1% MGBG in Vehicle N 
exceeded that of 10 % MGBG in saline. Vehicle Nand C10MSO 
vehicles also produced a significant increase in MGBG epider-
mal content compared to saline and N-methylpyrrolidone ve-
hicles (Table I) . 
In Vivo Studies 
Epidermal hyperplasia characterized by acant hosis (Figs 3A, 
4A,C) and increased DNA synthesis (Table II) was produced 
by topical application of Vehicle N in both normal and TPA-
t reated mice. Repeated topical applications of 10% MGBG in 
Vehicle N da ily fo r 3 days (3X) and/or 7 days (7x) caused 
marked epidermal atrophy as a resul t of epidermal cell destruc-
tion seen histologically in both normal (Fig 3B) and TPA-
stimulated ep idermis (Fig 4B,D). 
Topical MGBG (X3) or systemic MGBG had no effect on 
epidermal DNA synthesis in normal mouse skin , whereas top-
ical MGBG (x7) produced 50 % inhibi t ion of DNA synthesis 
(Table II) . In TPA-stimulated epidermis, topical MGBG (x3) 
and (X7) produced 41 % and 81 % inhibition of epidermal DNA 
synthesis, respectively (Table II) . The low levels of SAMDC in 
normal hairless mouse epidermis are induced 6- to 7-fold be-
tween 9- 12 h following a single application of 17 nmol TP A 
[10]. In t he present study, the topical application of MGBG 
(X3) and (x7) resulted in increased SAMDC levels compared 
to vehicle controls in TPA-stimulated epidermis (Table III) . 
The hyperproliferation produced by the 7 daily applications of 
Vehicle N resul ted in a 10-fold increase in SAMDC compared 
TABLE II. Effect of topical a.nd systemic M GBG on epidermal DNA 
syntheois 
CPM/ 11G DNA % In hibi tio n 
Normal mice 
Vehicle N cont rol (x3) 5.3 ± 2.2 
T opical MGBG (x3) 7.0 ± 2.0 - 0-
Vehicle N cont rol (X7) 10.7 ± 1.6 
T opical MGBG (x7) 5.4 ± 0.6 50 (p < 0.0005) 
U ntreated cont rol 3.4 ± 0.4 
Systemic MGBG 4.3 ± 1.7 - 0-
TPA-treated mice 
Vehicle N control (X3) 25.5 ± 4.8 
T opical MGBG (x3) 15.0 ± 3.5 41 (p < 0.025) 
Vehicle N cont rol (X?) 17.1± 4.8 
T opical MGBG (x7) 3.9 ± 1.2 86 (p < 0.0005) 
Topical applications of MGBG (10%) in Vehicle N, o r Vehicle N 
(cont rol) and systemic MGBG administration (50 mg/kg X 2) to normal 
and TPA-treated mice is described in Materials and M ethods. Each 
treatment group consisted of 6 mice. 
to t he TPA control. Systemic MGBG produced an enhance-
ment of SAMDC activity similar to t hat produced by t he topical 
(x3) application. 
In TPA-treated mice top ical MGBG (x3) produced a 2-fold 
increase in put rescine (control = 17 ± 3 nmol/ mg protein), 
with a 30% decrease in spermidine (control = 86 ± 1 nmol/ mg 
protein) and no change in spermine levels (control = 8 ± 1 
nmol/ mg protein) (Fig 5). After 7 days of t reatment (Vehicle 
N X 7 controls: putrescine, 27 ± 4 nmol/mg protein; spermidine, 
Nov. 1983 
TABLE Ill. Effect of topica l and systemic MGBG on TPA-stimulated 
epidermal SAM DC 
Treatment 
Veh icle N (x3) 
Topical MGBG (x3) 
Veh icle N (x?) 
Top ical MGBG (x?) 
C ont rol 
Systemic MGBG 
SAM DC activity 
(pmol/C02 released/ h/ mg protein} 
17 ± 4 
118 ± 45 
605 ± 247 
1460 ± 273 
18 ± 8 
130 ± 45 
Animals were treated with topical applications of MGBG (10%) in 
Ve hicle N, or Vehicle N (control) daily for 3 or 7 days or MGBG was 
adm ini te red systemically (50 mg/ kg) at 6 and 12 h prior to sacrifice. 
A ll ani mals received topical application of TPA (17 nmol) 12 h prior 
to sac rifice to stimulate SAMDC. 
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FIG 5. Effects of topical 10% MGBG in Vehicle N applied daily X3 
or dai ly x? on epidermal polya mine levels in TPA-treated mice. Resul ts 
are expressed as percent of Vehicle N treated control (mean ± SD) . 
65 ± 2 nmol/ mg prote in ; spermine, 7 ± 1 nmol/mg protein ), 
t he p utrescine and spermine levels dropped to ha lf of t he 
controls, with a 70 % decrease in spermidine. 
DISCUSSION 
The elevat ion of ep idermal polyamine levels in psorias is a nd 
t heir norma lization by various effective t reatm ent moda lit ies 
provides a basis for t he potential t herapeutic use of inhibitors 
of polyamine biosynt hesis. MGBG , a competitive inhibitor of 
SAMDC, is a potent ant iproliferative agent used in t he t reat-
ment of malignant disease. The substantial cytotoxic side ef-
fects of MGBG preclude its systemic use in a ben ign disease 
such as psoriasis. Topical app lication of MGBG (10 % in saline) 
has been sh own to produce a pa rtial t herapeutic response in 
psoriasis [5]. In t he present investigation we have shown t hat 
Vehicle N provides enhanced topical delivery of MGBG , with 
penetration of 0.1% MGBG in Vehicle N exceeding t hat of 10 % 
in saline. 
The rapid rate of synt hesis of the target enzyme, SAMDC, 
requires t he continued presence of high concent rations of 
MGBG to maintain an inhibitory effect in vivo [12]. The 
increased penetration of MGBG in Vehicle Nand t he sustained 
release achieved by t he topical route may optimize t he t hera-
peutic activity of MGBG. 
The effects of topical MGBG on epidermal polyamines and 
t heir biosynthetic en zymes were entirely as predicted from 
other systems [1 2]. The increase in epidermal SAMDC levels 
suggests an extended ha lf-life or stabilization as a consequence 
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of MGBG binding. The funct iona l inhibition of SAMDC is 
supported by t he ini tial increase in putrescine levels . T he 
minimal effect on spermidine and no effect on spe rmine after 
3 daily applications is consisten t with t he slower rates of 
degradation of t hese polyamines once they have been synthe-
sized in vivo. T he decrease in a ll polyamine levels after t reat-
ment for 7 days may reflect t he extensive ep idermal destruction 
as seen histologica lly. 
T he decrease in polyamine levels in TPA-treated hyperpro-
li ferative ep ide rmis is associated with a n inhibi t ion of DNA 
synt hesis resu lting in a n atrophic epidermis presumably from 
a marked decrease in cell proliferat ion. In view of the substan-
t ial increase in pe rcutaneous penetration of this topical MGBG 
formulation and its biochemical effects on hyperproliferative 
ep idermis, t hi s preparation may be useful for t he treatment of 
psoriasis and other hyperproli fe rative cutaneous diseases as -
sociated wi t h inc reased polyamine synt hesis. 
Topical treatment with a-dif1uoromethyl ornithine (DFMO), 
an irreve rsible inhibito r of ODC (Fig 1) has recen t ly been shown 
to produce moderate clinical improvement in psoriasis [13]. 
Kousa et a l [14] have show n t hat t he intradermal administra-
tio n of MGBG or DFMO causes a depletion of polyamine levels 
in psoriasis. T he "priming" effect of DFMO to enhance epider-
ma l accumulation of MGBG has recen t ly been demonstrated 
in mouse skin [15,16] . Further research directed toward t he 
combination of top ical DMFO and MGBG may lead to a more 
effective a nd less tox ic therapeutic regimen for the treatment 
of psoriasis and other hyperproliferative cutaneou s disorders . 
The authors wish to thank Dr. Peter McCann and Keith Diekema 
of Merrell Research for their assistance in the polyam ine analysis. 
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Diagnostic Criteria in Sezary's Syndrome: A Multiparameter Study of 
Peripheral Blood Lymphocytes in 32 Patients with Erythroderma 
REIN WILLEMZE, M.D., WILLEM A. VAN VLOTEN, M .D., Jo HERMANS, PH.D., 
MIEKE J. M. DAMSTEEG, B. Sc., AND CHRIS J. L. M. MEIJER, M.D. 
Departments of Dermatology (RW, WAvV), Pathology (MJMD), and Medical Statistics (JH), University Hospital, Leiden, and Pathological 
Institute (CJLMM), Free University, Amsterdam, The Netherlands 
In order to define additional diagnostic criteria for 
the early diagnosis of Sezary's syndrome (SS), periph-
eral blood lymphocytes of 32 patients with erythro-
derma, including 8 patients with SS, 4 patients with 
erythrodermic mycosis fungoides, 14 patients with an 
erythroderma on the basis of atopic or chronic derma-
titis, and 6 patients with erythrodermic psoriasis, were 
investigated by computer-assisted morphometry. The 
degree of nuclear indentation, expressed as the nuclear 
contour index (NCI), was measured on electron micro-
graphs. The mean NCI and the percentages of cerebri-
form mononuclear cells (CMC), defined by a NCI:;;. 6.5, 
were calculated. In addition, the percentages of lympho-
cytes, T and B cells, and the distribution ofT-cell sub-
populations as defined by Fc-receptors (TIL, T'Y) and 
monoclonal antibodies (0KT3, OKT4, OKT8, HLA-DR) 
were determined. 
Statistical analysis showed as most discriminating pa-
rameters for the differentiation between SS and benign 
forms of erythroderma: high percentages of lympho-
cytes (50% or more), an expanded OKT3+, OKT4+ pop-
ulation with an OKT4/0KT8 ratio > 10, a mean NCI 
value :;;. 5.5, the presence of more than 20% CMC, as 
well as the presence of cells with a NCI:;;. 11.5. The total 
leukocyte and lymphocyte counts, as well as the per-
centages of B, T, TI-L, and T'Y cells had limited value for 
the early diagnosis of SS. 
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Abbreviations: 
CMC: ce rebriform mononuclear ce lls 
CTCL: cutaneous T -celllymphoma 
FCS: fetal ca lf se rum 
MF: mycosis fungoides 
NC I: nuclear contour index 
PBS: phosphate-buffered saline 
SS: Sezary's syndrome 
Sezary's syndrome (SS), first described in 1938 [1] is clini-
cally characterized by a pruritic exfoliative or infiltrated ery-
throderma, lymphadenopathy, and the presence of atypical 
mononuclear cells (Sezary cells) in the peripheral blood [2,3]. 
At present most investigators regard SS as a neoplastic disease 
and part of the spectrum of cutaneous T-cell lymphomas 
(CTCL) [4,5]. In the early stage of the disease the clinical and 
histologic features are not diagnostic and differentiation from 
erythroderma on the basis of chronic dermatitis, atopic der-
matitis, or psoriasis is difficult. In these patients with generally 
normal leukocyte counts the diagnosis rests mainly upon dem-
onstration of Sezary cells in the peripheral blood. However, 
objective criteria for recognition of Sezary cells by light mi-
croscopy are lacking [6]. Moreover, ultrastructural studies have 
demonstrated t he presence of cerebriform mononuclear cells 
(CMC), similar to those in SS, in the peripheral blood of 
patients with generalized benign dermatoses [7] . 
In order to define additional diagnostic criteria for the early 
diagnosis of SS, we have performed computer-assisted mor-
phometry and marker studies of peripheral blood lymphocytes 
of 32 patients with erythroderma, including 8 patients with SS, 
4 with erythrodermic mycosis fungoides (MF) , and 20 patients 
with various benign forms of erythroderma. 
MATERIALS AND METHODS 
Patients 
Heparinized venous blood was obtained from 32 patients with ery-
throderma including 8 patients with SS, 4 with erythrodermic MF, 14 
with chronic dermatitis, and 6 with psoriasis. The peripheral blood 
from 10 healthy donors served as controls. 
The diagnosis of SS was based on clinical and histologic criteria: 
eryth roderma, lymphadenopathy, a nd the presence of hyperconvoluted 
lymphoid cells, compatible with Sezary cells, in the peripheral blood. 
The patients with erythrodermic MF had shown the classica l Alibert-
Bazin type of MF"for 3 months (see Table I, no. 9) to more than 4 
years (nos. 10- 12) before the erythroderma developed. At the t ime of 
study all patients had enlarged inguinal lymph nodes. Histologic ex-
amination showed dermatopathic lymphadenopathy in 2 patients (nos. 
9 and 10), early involvement according to the criteria of Scheffer et al 
[8] in 1 patient (no. 11), and diffuse MF involvement in another patient 
(no. 12) with progressive leukemic disease, which proved to be fatal 
within 5 months. The clinical data of the patients with SS and MF at 
the time of study are shown in Table I. 
